Coronavirus - we're here to help
From how to access your account online, scam awareness, your wellbeing and our community we're here to help.

Skip to main content
  • Register
  • Help
  • Contact us
  • Log in to HL Account

Ergomed plc (ERGO) Ordinary 1p

Sell:844.00p Buy:860.00p 0 Change: 2.00p (0.24%)
FTSE AIM 100:0.04%
Market closed Prices as at close on 25 November 2020 Prices delayed by at least 15 minutes | Switch to live prices |
Sell:844.00p
Buy:860.00p
Change: 2.00p (0.24%)
Market closed Prices as at close on 25 November 2020 Prices delayed by at least 15 minutes | Switch to live prices |
Sell:844.00p
Buy:860.00p
Change: 2.00p (0.24%)
Market closed Prices as at close on 25 November 2020 Prices delayed by at least 15 minutes | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Ergomed plc is a provider of drug development services to the pharmaceutical industry. The Company operates through two segments: clinical research services (CRS), and drug safety and medical information services (DS&MI;). It provides a range of clinical trial planning, management and monitoring services. It is focused on oncology, neurology and immunology, and the development of orphan drugs. It has two businesses: Services Business and Co-Development Business. The Services Business is a clinical research business providing services to the pharmaceutical and biotechnology industry. The Co-Development Business is a portfolio of partnerships with pharmaceutical and biotechnology companies, providing its drug development services in exchange for a carried interest in any revenues attributable to the drug asset, including out licensing milestones, as well as sales of the product. It provides clinical development, trial management and pharmacovigilance services to over 100 clients.

Contact details

Address:
1 Occam Court, Occam Road
GUILDFORD
GU2 7HJ
United Kingdom
Telephone:
+44 (01483) 503205
Website:
www.ergomedplc.com/

Important dates

Future events
There are no future events available.
Past events
General meeting 19 October 2020 19/10/20
Interim results 22 September 2020 22/09/20
Trading Announcement 21 July 2020 21/07/20
AGM 10 June 2020 10/06/20
Annual report 15 May 2020 15/05/20
Final results 25 March 2020 25/03/20
Trading Announcement 29 January 2020 29/01/20

General stock information

EPIC:
ERGO
ISIN:
GB00BN7ZCY67
Market cap:
£415.08 million
Shares in issue:
48.72 million
Sector:
Pharmaceuticals & Biotechnology
Exchange:
London Stock Exchange
Currency:
Sterling pence
Indices:
FTSE AIM 100,FTSE AIM All Share

Key personnel

  • Miroslav Reljanovic
    Executive Vice Chairman of the Board
  • Richard Barfield
    Chief Financial Officer, Executive Director
  • Lewis Cameron
    Chief Operating Officer, Director
  • Danko Dominis
    Ergomed Head of Business Development
  • Branka Duvnjak
    Ergomed Head of Site Management
  • Terry Murdock
    President of North America, Executive Director of Global Clinical Operations
  • Chris Wilson
    Head of Quality and Regulatory

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by NBTrader.

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.